New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced ...
Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge Poster Number: L58 Session: Late ...
Financing led by Investissement Québec with continued support from long-standing investorsPlans include the acceleration of clinical development ...
Structure Therapeutics (GPCR) is drawing attention as its lead oral obesity candidate, GSBR-1290, advances through phase 2 trials, with analyst ratings shaping current sentiment around the stock. See ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...
Immuno-oncology and inflammation startup Kainova Therapeutics has announced the successful first close of its Series B ...
G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast potential for GPCR-targeting drugs in treating a range of health conditions, ...
Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...
Exicure (NASDAQ:XCUR) signed a MOU with GPCR Therapeutics aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results